Story perspectives

MIT's Breakthrough Antibody Nanoparticles Target and Eliminate Tumors

9/10/2025

25 5

Summary

Story summary

MIT chemists created antibody-bottlebrush prodrug conjugates for targeted cancer therapy.
These nanoparticles deliver more chemotherapy directly to tumor cells, enhancing drug delivery through specific antibodies.
In mouse models, they successfully eliminated tumors in breast and ovarian cancer.
This approach enables the use of less potent drugs, expanding treatment options.
The research surpassed FDA-approved antibody-drug conjugates in effectiveness and was published in Nature Biotechnology.

1 of 1

Story summary

MIT chemists created antibody-bottlebrush prodrug conjugates for targeted cancer therapy.
These nanoparticles deliver more chemotherapy directly to tumor cells, enhancing drug delivery through specific antibodies.
In mouse models, they successfully eliminated tumors in breast and ovarian cancer.
This approach enables the use of less potent drugs, expanding treatment options.
The research surpassed FDA-approved antibody-drug conjugates in effectiveness and was published in Nature Biotechnology.